Thyroid Cancer Drugs Global Market Report 2024

Description

“Thyroid Cancer Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thyroid cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thyroid cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The thyroid cancer drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Type: Ipilimumab; Cabozantinib-S-Malate; Caprelsa (Vandetanib); Doxorubicin Hydrochloride; Lenvatinib Mesylate; Nivolumab; Vandetanib; Other Drug Types
2) By Type: Radioiodine Ablation; Thyroid Stimulating Hormone (THS) Suppression; Chemotherapy; Targeted Multikinase Therapy; Other Types
3) By End Users: Hospitals; Oncology Clinics; Research Organizations; Other End-Users
Companies Mentioned: Mylan Pharmaceuticals Inc.; Alara Pharmaceutical Corporation; Baxter International Inc.; Abbott Laboratories; APP Pharmaceuticals LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Thyroid cancer drugs are pharmaceutical agents utilized in the treatment of thyroid cancer. These drugs work by inhibiting various kinase proteins, primarily by preventing the formation of new blood vessels that cancer cells require for growth. They target specific proteins that cancer cells often produce to facilitate their growth. Thyroid cancer typically originates in the thyroid tissue, composed of follicular cells and parafollicular cells.

The main categories of thyroid cancer drugs include radioiodine ablation, thyroid stimulating hormone (TSH) suppression, chemotherapy, targeted multikinase therapy, and other therapeutic approaches. Radioiodine ablation is a form of radiation therapy that employs radioactive iodine to eliminate or ablate any remaining healthy thyroid tissue following a thyroidectomy. Various drugs are used in the treatment of thyroid cancer, including ipilimumab, cabozantinib-s-malate, caprelsa (vandetanib), doxorubicin hydrochloride, lenvatinib mesylate, nivolumab, vandetanib, and others. These drugs find applications in sectors such as hospitals, oncology clinics, research organizations, and others as part of thyroid cancer treatment.

The thyroid cancer drugs market research report is one of a series of new reports from The Business Research Company that provides thyroid cancer drugs market statistics, including thyroid cancer drugs industry global market size, regional shares, competitors with a thyroid cancer drugs market share, detailed thyroid cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. This thyroid cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.01 billion in 2023 to $1.16 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The expansion observed during the historical period can be attributed to several factors, including the increasing incidence of thyroid cancer, advances in medical research leading to the development of effective treatments, a favorable regulatory environment that facilitates drug approvals, and the overall growth in healthcare expenditure to address thyroid cancer and related treatments.

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $1.96 billion in 2028 at a compound annual growth rate (CAGR) of 14.1%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing prevalence of thyroid cancer due to an aging population, advancements in precision medicine leading to more tailored treatments, the development of healthcare infrastructure to support cancer care, rising awareness and early detection efforts. Notable trends expected during the forecast period encompass the growth of personalized medicine in thyroid cancer treatment, the utilization of targeted therapies and immunotherapies, the expansion of clinical trials and drug pipelines, the development of combination therapies, the use of biomarker-driven treatments, and the increased use of telemedicine and remote monitoring for thyroid cancer care.

The thyroid cancer drugs market is experiencing growth due to the increasing incidences of thyroid cancer, especially in women. For example, in 2022, The American Cancer Society reported approximately 43,800 estimated new cases of thyroid cancer in the United States, with 31,940 cases in women and 11,860 cases in men, leading to 2,230 deaths from thyroid cancer. Among these fatalities, 1,070 are men, and 1,160 are women. This surge in thyroid cancer cases, particularly among women, is a driving force behind the growth of the thyroid cancer drugs market.

The expansion of the thyroid cancer drugs market in the future is expected to be driven by the rising healthcare expenditure. Healthcare expenditure encompasses spending on healthcare costs and plays a pivotal role in supporting the development and accessibility of thyroid cancer drugs. For instance, as of November 2022, the Canadian Institute for Health Information, a US-based non-profit organization, noted that healthcare expenditure had increased to 0.8%, amounting to $331 billion in 2022, following a 7.6% rise in 2021. This uptick in healthcare expenditure is a key driver behind the growth of the thyroid cancer drugs market.

The increased use of targeted therapies in thyroid cancer treatment is acting as a restraint on the thyroid cancer drugs market. Targeted therapies specifically target cancer-related genes, proteins, and tissues that promote the growth and survival of cancer cells. They are becoming more prevalent in thyroid cancer treatment, especially as traditional thyroid hormone-based therapies are ineffective against certain cancers. For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used for advanced medullary thyroid cancer (MTC). As patients increasingly turn to targeted therapies for treatment, the demand for traditional thyroid cancer drugs is decreasing, impacting the overall growth of the market.

The use of combination drugs in thyroid cancer treatment is growing due to their effectiveness in preventing cancer progression. Combination drugs consist of two or more active pharmaceutical ingredients (APIs) in a single dosage form. These drugs help reduce the development of drug resistance and inhibit the growth of cancer cells. For instance, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

Major companies operating in the thyroid cancer drugs market are innovating to drive revenue growth. One such example is CABOMETYX, a prescription medicine used to treat various cancer types, including kidney cancer (renal cell carcinoma), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and is radioactive iodine-refractory or ineligible. In September 2021, Exelixis announced the U.S. FDA approval of CABOMETYX for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer.

In August 2022, Bristol Myers Squibb, a U.S.-based pharmaceutical company, acquired Turning Point Therapeutics for an undisclosed amount. This strategic acquisition expands BMS's portfolio, particularly in the development of precision medicine for cancer patients, including thyroid cancer drugs.

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline PLC, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic PLC, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the thyroid cancer drugs market in 20232. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the thyroid cancer drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r9253

1. Executive Summary

2. Thyroid Cancer Drugs Market Characteristics

3. Thyroid Cancer Drugs Market Trends And Strategies

4. Thyroid Cancer Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Thyroid Cancer Drugs Market Size and Growth

5.1. Global Thyroid Cancer Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Thyroid Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Thyroid Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Thyroid Cancer Drugs Market Segmentation

6.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Ipilimumab
Cabozantinib-S-Malate
Caprelsa (Vandetanib)
Doxorubicin Hydrochloride
Lenvatinib Mesylate
Nivolumab
Vandetanib
Other Drug Types
6.2. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Radioiodine Ablation
Thyroid Stimulating Hormone (THS) Suppression
Chemotherapy
Targeted Multikinase Therapy
Other Types
6.3. Global Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Oncology Clinics
Research Organizations
Other End-Users

7. Thyroid Cancer Drugs Market Regional And Country Analysis

7.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Thyroid Cancer Drugs Market

8.1. Asia-Pacific Thyroid Cancer Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Thyroid Cancer Drugs Market

9.1. China Thyroid Cancer Drugs Market Overview
9.2. China Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Thyroid Cancer Drugs Market

10.1. India Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Thyroid Cancer Drugs Market

11.1. Japan Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Thyroid Cancer Drugs Market

12.1. Australia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Thyroid Cancer Drugs Market

13.1. Indonesia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Thyroid Cancer Drugs Market

14.1. South Korea Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Thyroid Cancer Drugs Market

15.1. Western Europe Thyroid Cancer Drugs Market Overview
15.2. Western Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Thyroid Cancer Drugs Market

16.1. UK Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Thyroid Cancer Drugs Market

17.1. Germany Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Thyroid Cancer Drugs Market

18.5. France Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Thyroid Cancer Drugs Market

19.9. Italy Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Thyroid Cancer Drugs Market

20.13. Spain Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Thyroid Cancer Drugs Market

21.1. Eastern Europe Thyroid Cancer Drugs Market Overview
21.2. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Thyroid Cancer Drugs Market

22.1. Russia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Thyroid Cancer Drugs Market

23.1. North America Thyroid Cancer Drugs Market Overview
23.2. North America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Thyroid Cancer Drugs Market

24.1. USA Thyroid Cancer Drugs Market Overview
24.2. USA Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Thyroid Cancer Drugs Market

25.1. Canada Thyroid Cancer Drugs Market Overview
25.2. Canada Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Thyroid Cancer Drugs Market

26.1. South America Thyroid Cancer Drugs Market Overview
26.2. South America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Thyroid Cancer Drugs Market

27.1. Brazil Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Thyroid Cancer Drugs Market

28.1. Middle East Thyroid Cancer Drugs Market Overview
28.2. Middle East Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Thyroid Cancer Drugs Market

29.1. Africa Thyroid Cancer Drugs Market Overview
29.2. Africa Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Thyroid Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Thyroid Cancer Drugs Market Competitive Landscape And Company Profiles

30.1. Thyroid Cancer Drugs Market Competitive Landscape
30.2. Thyroid Cancer Drugs Market Company Profiles
- 30.2.1. Mylan Pharmaceuticals Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Alara Pharmaceutical Corporation
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Baxter International Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Abbott Laboratories
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. APP Pharmaceuticals LLC
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Thyroid Cancer Drugs Market Competitive Benchmarking

32. Global Thyroid Cancer Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Thyroid Cancer Drugs Market

34. Thyroid Cancer Drugs Market Future Outlook and Potential Analysis

34.1 Thyroid Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Thyroid Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Thyroid Cancer Drugs Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer